miR-582-5p Regulates Cell Stemness and Recurrence in Bladder Cancer via Targeting CD81

Author:

Xie Tianlei1,Zhang Xuyu1,Zhang Zhongqing1,Cao Wenmin2,Chen Wei2,Guo Hongqian1,Zhuang Junlong1

Affiliation:

1. Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China

2. Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China

Abstract

To explore the underlying molecular mechanism of cancer stem cells (CSCs) driving bladder cancer (BC) recurrence and progression. Tumor xenograft model in vivo was established after 4–6-week-old male nude mice were subcutaneously injected with 5×106 of T24 and 5637 cells in 0.1 mL 50% Matrigel. Pearson correlation analysis analyzed the correlation between miR-582-5p and CD81, and which was furtherly verified by dual-luciferase reporter gene assay. Sphere formation assay, flow cytometry, immunohistochemistry (IHC), qRT-PCR and Western blot were carried to examine sphere formation, ALDHhigh populations, the level of genes and proteins. Multivariate analysis was carried to explore the factors associated with recurrence free survival of BC patients. miR-582-5p was down-regulated in patients with BC, and miR-582-5p overexpression negatively correlated with BC stemness. Mechanically, miR-582-5p negatively targeted to CD81. Functionally, miR-582-5p overexpression inhibited BC stemness and recurrence via targeting CD81. Our study illustrated that miR-582-5p inhibited cell stemness and recurrence via targeting CD81 in BC. Our findings illustrated the specific molecular mechanism of miR-582-5p inhibiting BC progression. miR-582-5p may serve as the novel biomarker for BC clinical therapeutics and prognosis.

Publisher

American Scientific Publishers

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3